Remove 2020 Remove Illness Remove Individual Remove Patients
article thumbnail

Aftershock in Academia: Assessing COVID-19s Impact on Schizophrenia Patients in Academic Medical Centers [Behavioral, psychosocial, and mental illness]

Annals of Family Medicine

Context: The impact of the COVID-19 pandemic on individuals with schizophrenia who are admitted to academic medical centers (AMCs) has not been previously reported. Objective: To examine the epidemiology and mortality among schizophrenia patients discharged from AMCs in the U.S. from Oct 2019 to Dec 2023. Setting: AMCs within the US.

article thumbnail

A Long Time Coming: DEA Regs Finally Authorize Schedule II Prescription Partial Fills

FDA Law

CARA amended the Controlled Substances Act (“CSA”) to enable physicians or patients to request pharmacists to partially fill prescriptions for schedule II substances including opioids and to allow remaining quantities to be filled up to 30 days after issuance of the prescription (up to 72 hours for emergency oral prescriptions). 21 U.S.C. §

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Episode 120: Antiracism in Medicine Series Episode 1 – Racism, Police Violence, and Health

The Clinical Problem Solvers

Pearls Defining Structural Racism Structural racism is a term that acknowledges that racism is perpetuated beyond individual interactions and interpersonal racism, but is present in the systems and policies that govern our everyday lives.

article thumbnail

A Question 30 Years in the Making: Would a Final LDT Rule Withstand Judicial Scrutiny?

FDA Law

The PR first sets out to establish that it has authority to regulate in vitro diagnostic “test systems” as devices, and not just the system’s individual components, such as reagents, instruments, specimen collection devices, and software.

article thumbnail

Deprescribing Super Special Part II: Podcast with Elizabeth Bayliss, Ariel Green, and Kevin McConeghy

GeriPal

My take home from this is that while the most preferred explanation for deprescribing statins and sedative-hypnotics is one focused on the risk of side effects, we also need to individualize it to the patient and the medication that they are taking. But how to talk to patients about the risk and benefits when starting.

article thumbnail

Diabetes in Late Life: Nadine Carter, Tamryn Gray, Alex Lee

GeriPal

When I’m on palliative care consults and attending in our hospice unit we have to counsel patients about deprescribing and de-intensifying diabetes medications. And we invited Tamryn Gray from the Dana Farber joins us to ask insightful questions, including: What blood sugar range should we target for patients in the nursing home or hospice?

article thumbnail

Episode 236: ARM Episode 16 – Live from SGIM: Best of Antiracism Research at the Society of General Internal Medicine’s 2022 Annual Meeting

The Clinical Problem Solvers

Dr. Davila is a palliative care physician at Massachusetts General Hospital and her work examines racial and ethnic inequities in patient-clinician communication. Individuals who believe that genetic differences explain racial differences in health outcomes are more likely to practice race-based medicine.